The drug is now manufactured at a US FDA-approved facility

Cadila Pharmaceuticals has introduced Vasograin EC, a reformulated version of Vasograin with a US FDA-approved formulation.

Vasograin EC is formulated to deliver rapid and long-lasting migraine relief. Its reduced tablet size enhances patient compliance, comfort, and adherence, empowering individuals to regain control of their daily lives. As demand for effective migraine management continues to rise, Cadila Pharmaceuticals remains at the forefront, offering innovative and accessible healthcare solutions.